/
RLYB
$16.00-$0.06 (-0.37%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$92.8M
6M shares
52-week range
$2.55 – $17.57
90% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
11.30%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-96.80
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $636.0K | $858.0K |
| Cost of revenue | $26.3K | $62.0K | $109.0K | $167.0K | $150.0K | $131.0K | $92.0K |
| Gross profit | −$26.3K | −$62.0K | −$109.0K | −$167.0K | −$150.0K | $636.0K | $766.0K |
| Gross margin | — | — | — | — | — | 100.0% | 89.3% |
| R&D | $11.4M | $17.6M | $26.9M | $40.7M | $53.5M | $41.5M | $19.6M |
| Operating income | −$17.6M | −$25.3M | −$45.6M | −$67.9M | −$78.9M | −$60.5M | −$28.1M |
| EBITDA | −$17.4M | −$25.2M | −$45.4M | −$67.7M | −$78.8M | −$60.4M | −$28.0M |
| Net income | −$17.6M | −$26.4M | −$47.0M | −$66.7M | −$74.6M | −$57.8M | −$9.0M |
| Net margin | — | — | — | — | — | -9084.1% | -1046.4% |
| EPS (diluted) | -6.32 | -9.52 | -11.68 | -16.72 | -14.72 | -10.64 | -1.59 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $80000 | $-5.52 | $-5.52–$-5.52 | 1 |
| 2027 | $88M | $-11.52 | $-11.52–$-11.52 | 1 |
| 2028 | $88M | $-3.12 | $-3.12–$-3.12 | 1 |
| 2029 | $89M | $3.92 | $3.92–$3.92 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$11.07
Price
$16.00
Implied downside
-31%
Peer comparison
Rallybio Corporation Common Stock
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
www.rallybio.com- Employees
- 9
- IPO / List date
- Jul 29, 2021
- HQ
- NEW HAVEN, CT
Held by traders on TradeandTell
No one on the platform currently holds RLYB.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 156,527 | $1.4M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-02-06 | 1-for-8reverse |
Recent trades on TradeandTell
No one on the platform has traded RLYB yet.
